» Articles » PMID: 6423543

Efficacy of Mycobacterium Bovis BCG Vaccination in Mice Undergoing Prior Pulmonary Infection with Atypical Mycobacteria

Overview
Journal Infect Immun
Date 1984 Apr 1
PMID 6423543
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The efficacy of Mycobacterium bovis BCG immunization in mice with established pulmonary infections caused by atypical mycobacteria was studied. In all four strains of Mycobacterium tested (M. kansasii, M. simiae, M. avium, and M. scrofulaceum), intravenous inoculation with 10(6) BCG had no discernible effect upon the course of atypical mycobacterial infection within the lungs; despite this, however, all BCG-vaccinated groups of mice were fully resistant to a subsequent acute aerogenic challenge with M. tuberculosis H37Rv, regardless of the presence of the pulmonary atypical mycobacterial infections. Furthermore, animals infected with M. kansasii, M. simiae, or M. avium but not vaccinated with BCG expressed considerable antituberculous resistance within the lungs, resulting in significant prolonged survival of these animals. The relevance of these findings to the expression of antituberculous resistance in human populations in areas in which atypical mycobacteria are endemic and the failure of these findings to support the hypothesis that prior contact with atypical mycobacteria might in some way jeopardize or interfere with the efficacy of subsequent BCG vaccination are discussed.

Citing Articles

Effects of non-tuberculous mycobacteria on BCG vaccine efficacy: A narrative review.

Ghasemi F, Kardan-Yamchi J, Heidary M, Karami-Zarandi M, Akrami S, Maleki A J Clin Tuberc Other Mycobact Dis. 2024; 36:100451.

PMID: 38764556 PMC: 11101679. DOI: 10.1016/j.jctube.2024.100451.


Vaccination of White-Tailed Deer with Bacillus Calmette-Guérin (BCG): Effect of ssp. Infection.

Palmer M, Kanipe C, Lehman K, Thacker T, Putz E, Boggiatto P Microorganisms. 2023; 11(10).

PMID: 37894146 PMC: 10609214. DOI: 10.3390/microorganisms11102488.


Mucosal exposure to non-tuberculous mycobacteria elicits B cell-mediated immunity against pulmonary tuberculosis.

Dutt T, Karger B, Fox A, Youssef N, Dadhwal R, Zohaib Ali M Cell Rep. 2022; 41(11):111783.

PMID: 36516760 PMC: 10337594. DOI: 10.1016/j.celrep.2022.111783.


Vaccine Vector Elicits CD4+ Th17 and CD8+ Tc17 T Cells With Therapeutic Potential to Infections With .

Kannan N, Haug M, Steigedal M, Flo T Front Immunol. 2020; 11:1116.

PMID: 32582196 PMC: 7296097. DOI: 10.3389/fimmu.2020.01116.


Outcome of shorter treatment duration in non-cavitary nodular bronchiectatic complex lung disease.

Park Y, Chong Y, Kim Y, Kim O, Kwon B, Shim T J Thorac Dis. 2020; 12(3):338-348.

PMID: 32274100 PMC: 7138995. DOI: 10.21037/jtd.2020.01.39.


References
1.
Rook G, Bahr G, Stanford J . The effect of two distinct forms of cell-mediated response to mycobacteria on the protective efficacy of BCG. Tubercle. 1981; 62(1):63-8. DOI: 10.1016/0041-3879(81)90038-6. View

2.
WOLINSKY E . Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis. 1979; 119(1):107-59. DOI: 10.1164/arrd.1979.119.1.107. View

3.
YOUMANS G, PARLETT R, YOUMANS A . The significance of the response of mice to immunization with viable unclassified mycobacteria. Am Rev Respir Dis. 1961; 83:903-5. DOI: 10.1164/arrd.1961.83.6.903. View

4.
Palmer C, Long M . Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis. 1966; 94(4):553-68. DOI: 10.1164/arrd.1966.94.4.553. View

5.
Stanford J, Shield M, Rook G . How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle. 1981; 62(1):55-62. DOI: 10.1016/0041-3879(81)90037-4. View